Ionis Pharmaceuticals, Inc. (IONS) News

Ionis Pharmaceuticals, Inc. (IONS): $38.75

2.15 (+5.87%)

POWR Rating

Component Grades













Filter IONS News Items

IONS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IONS News Highlights

  • For IONS, its 30 day story count is now at 59.
  • Over the past 25 days, the trend for IONS's stories per day has been choppy and unclear. It has oscillated between 1 and 35.
  • The most mentioned tickers in articles about IONS are PFE, DRUG and AX.

Latest IONS News From Around the Web

Below are the latest news stories about Ionis Pharmaceuticals Inc that investors may wish to consider to help them evaluate IONS as an investment opportunity.

Analysts Are More Bearish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Than They Used To Be

One thing we could say about the analysts on Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) - they aren't optimistic...

Yahoo | February 25, 2022

Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up

Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.

Yahoo | February 25, 2022

Company News for Feb 25, 2022

Companies in The News Are: AEP,ATHM,IONS,DISH

Yahoo | February 25, 2022

Ionis PharmaceuticalsEPS of $1.41, revenue of $440M beats by $155.92M

Ionis Pharmaceuticals press release (NASDAQ:IONS): Q4 EPS of $1.41 may not be comparable to consensus of $0.31. Revenue of $440M (+51.7% Y/Y) beats by $155.92M. FY22 Guidance: Revenue to be greater than $575M vs. $659.54M consensus. Net Loss to be less than $275M...

Seeking Alpha | February 24, 2022

Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2021 Results - Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (IONS) Q4 2021 Results Earnings Conference Call February 24, 2022, 11:30 AM ET Company Participants Jennifer Capuzelo - Director of Investor Relation Brett Monia - Founder & CEO Beth Hougen - Chief Financial Officer Richard Geary - Executive Vice President & Chief Development Officer Eric Swayze -...

SA Transcripts on Seeking Alpha | February 24, 2022

Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Beat Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 76.25% and 30.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Ionis reports fourth quarter and full year 2021 financial results and recent business achievements

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year ended December 31, 2021, and recent business achievements.

Yahoo | February 24, 2022

Ionis Pharmaceuticals Q4 2021 Earnings Preview

Ionis Pharmaceuticals (NASDAQ:IONS) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is $0.31 and the consensus…

Seeking Alpha | February 23, 2022

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Rose 22.4% From Its 52-Week Low; YTD Numbers Rose 6.05% Here Are Some Things To Keep In Mind

During the last session, Ionis Pharmaceuticals Inc. (NASDAQ:IONS)s traded shares were 0.74 million, with the beta value of the company hitting 0.85. At the end of the trading day, the stocks price was $32.27, reflecting an intraday loss of -1.44% or -$0.47. The 52-week high for the IONS share is $58.46, that puts it down Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Rose 22.4% From Its 52-Week Low; YTD Numbers Rose 6.05% Here Are Some Things To Keep In Mind Read More »

Marketing Sentinel | February 19, 2022

Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8194 seconds.